DRUG NAME: Daratumumab

Human and animal studies are not available, however IgG1 monoclonal antibodies s are known to cross the placenta. Based on its mechanism of action, daratumumab may cause fetal myeloid or lymphoid cell depletion and decreased bone density. Women of childbearing potential should use effective contraception

  Causes, Known